ArticleAmerican journal of ophthalmology case reports2025
Resolution of subretinal fluid in intractable central serous chorioretinopathy with high-dose intravitreal aflibercept.
Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report an unusual case of a patient with intractable central serous chorioretinopathy with a dramatic treatment response to high-dose intravitreal aflibercept. Methods: Retrospective case report. Results: A 40-year-old female patient presented with decreased vision after use of intranasal fluticasone and recent life stressors and was diagnosed with central serous chorioretinopathy. Over a three-year period, she underwent numerous therapies, including seven sessions of photodynamic therapy, intravitreal bevacizumab, standard-dose intravitreal aflibercept, intravitreal faricimab, oral eplerenone, oral acetazolamide, and topical ketorolac, with minimal to no treatment response. After a single treatment with high-dose intravitreal aflibercept, 8 mg, she achieved resolution of subretinal fluid. Conclusion: High-dose intravitreal aflibercept may have a role in management of treatment-resistant central serous chorioretinopathy; further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.